Transforming Discovery into Opportunity

Announcing the Inaugural Cascadia Venture Forum – Seattle Summit…

Don’t miss this high energy event supporting the thriving life sciences innovation cluster that spans the entire Pacific Northwest!

Read more…


CDRD and Zucara Therapeutics have completed a license deal that provides access to Zucara to select lead drug candidate. Phase I clinical trials expected 2018.

Zucara is developing a first-in-class therapeutic focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.

Read more…

CDRD has launched a new spin-off company, Sepset Biosciences Inc. Sepset is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier & more targeted treatment of sepsis.

Read more…

Congrats to Microdermics who won the CDRD Life Sciences Award valued at $10,000 at the 2016 BCIC-New Ventures Competition.

In this photo: Mike Volker, Grant Campany, Jon Jafari

CDRD and the MS Society of Canada have issued a global call for research projects to discover and develop treatments for progressive MS.

Details here…


By looking at the commonalities in multiple rare diseases rather than just one specific disease, we are moving toward treating the root cause of rare diseases rather than managing the symptoms.

Find out how…

CDRD Expands Global Industry Partnerships with Addition of AstraZeneca!

This private/public partnership will continue to support Canadian health research projects by advancing promising research from the university labs through independent testing and validation and towards clinical trials and commercialization.

Read more…

Quark Venture has made a significant seed investment in Sitka Biopharma – a critical value-creating event that will enable Sitka to advance their lead compound for the treatment of bladder cancer into clinical trials.

Read more…

Health sciences researchers, entrepreneurs, and companies alike have the opportunity to collaborate with CDRD and thereby access its full suite of expertise, infrastructure, and broad partnerships and networks.

Find out how CDRD supports Canadian Small/Medium Enterprises (SMEs)……


  • Over 1,100 early-stage technologies evaluated for commercial potential
  • Over 200 projects on 134 distinct technologies
  • 56 technologies advanced toward commercialization and/or commercialized
  • 7 spin-off companies launched
  • 14 technologies out-licensed

What is CDRD?

Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.

We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.

In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.

Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).

Latest from the Blog

Microdermics Wins BCIC-New Ventures Competition & $10,000 in Commercial Support from CDRD

Zebrafish Core Facility at Dalhousie / CDRD Atlantic Node Receives Federal Investment to Build National Centre of Orphan Drug Research


Latest from Twitter


A Shared Vision

  • Industry
  • Academia
  • Government

Sign up to our newsletter

Receive CDRD's e-newsletter, The CDRD Pipeline and other e-communications for regular updates on all our news and activities.

© Copyright 2016 CDRD. All rights reserved.